FDA-approved

Digestive & weight

Tirzepatide

Evidence

FDA approved

Class

GIP and GLP-1 receptor agonist

/

Tirzepatide

KEY TAKEAWAY

Tirzepatide activates two gut hormone receptors, GIP and GLP-1. It is approved for type 2 diabetes and for chronic weight management. In a 72-week trial, adults on the highest dose lost about 20% of their body weight.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

A dual GIP and GLP-1 receptor agonist

Approved for

Type 2 diabetes and chronic weight management in adults

Key fact

Produced about 20% weight loss at the top dose in a 72-week trial

Route

Weekly injection

Evidence strength

FDA approved

What it is

What it is

Tirzepatide is a once-weekly injectable peptide built from the GIP sequence with changes that let it also act on the GLP-1 receptor. It is sold as Mounjaro and Zepbound.

How it works

How it works

By acting on both GIP and GLP-1 receptors it increases insulin release after meals, slows digestion and reduces appetite. The combined action appears to lower blood sugar and body weight more than GLP-1 activation alone.

Regulatory status

Regulatory status

The FDA approved tirzepatide for type 2 diabetes in 2022 and for chronic weight management in 2023. Only the branded products are approved.

What it is used for

What it is used for

Glycemic control in type 2 diabetes and long-term weight management in adults with obesity or overweight and a related condition.

Side effects and risks

Side effects and risks

Nausea, diarrhea, vomiting and constipation are common and usually ease over time. Gallbladder disease and pancreatitis are possible. Like semaglutide, the label includes a boxed warning about thyroid C-cell tumors in rodents.

Citations

Citations

Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo